GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVie Inc (NAS:BIVI) » Definitions » Return-on-Tangible-Equity

BioVie (BioVie) Return-on-Tangible-Equity : -260.91% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is BioVie Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. BioVie's annualized net income for the quarter that ended in Mar. 2024 was $-32.27 Mil. BioVie's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $12.37 Mil. Therefore, BioVie's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -260.91%.

The historical rank and industry rank for BioVie's Return-on-Tangible-Equity or its related term are showing as below:

BIVI' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -859.86   Med: -498.01   Max: -97.28
Current: -273.29

During the past 11 years, BioVie's highest Return-on-Tangible-Equity was -97.28%. The lowest was -859.86%. And the median was -498.01%.

BIVI's Return-on-Tangible-Equity is ranked worse than
90.49% of 1304 companies
in the Biotechnology industry
Industry Median: -46.86 vs BIVI: -273.29

BioVie Return-on-Tangible-Equity Historical Data

The historical data trend for BioVie's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVie Return-on-Tangible-Equity Chart

BioVie Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -859.86 -597.72

BioVie Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -263.59 -208.07 -408.39 -507.38 -260.91

Competitive Comparison of BioVie's Return-on-Tangible-Equity

For the Biotechnology subindustry, BioVie's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVie's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where BioVie's Return-on-Tangible-Equity falls into.



BioVie Return-on-Tangible-Equity Calculation

BioVie's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=-50.256/( (2.459+14.357 )/ 2 )
=-50.256/8.408
=-597.72 %

BioVie's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-32.272/( (6.623+18.115)/ 2 )
=-32.272/12.369
=-260.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


BioVie  (NAS:BIVI) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


BioVie Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of BioVie's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVie (BioVie) Business Description

Industry
Traded in Other Exchanges
N/A
Address
680 W Nye Lane, Suite 204, Carson, NV, USA, 89703
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Executives
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Cuong V Do director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Michael Edward Sherman director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Robert J Hariri director 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Joanne Wendy Kim officer: Chief Financial Officer C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Joseph M Palumbo other: Chief Medical Officer 616 BROOKSIDE AVENUE, SAINT DAVIDS PA 19087
Jonathan M Adams officer: EVP Liver Cirrhosis Programs 100 CUMMINGS CENTER 247C, BEVERLY MA 01915
Penelope Markham officer: EVP Liver Cirrhosis R&D C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Christopher Reading officer: EVP Neuroscience R&D C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Clarence N. Ahlem officer: EVP of Product Development 5305 RENAISSANCE AVE., SAN DIEGO CA 92122
Mina Sooch director 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Sigmund Rogich director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Patrick D Yeramian officer: Chief Medical Officer 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486

BioVie (BioVie) Headlines